Brief Article
Copyright ©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 14, 2011; 17(14): 1895-1902
Published online Apr 14, 2011. doi: 10.3748/wjg.v17.i14.1895
Table 1 Clinicopathological features and miR-622 expression in gastric cancer patients
FactorsNo. of patientsMean expression of miR-622P value
Age (yr)
< 65424.84 ± 3.780.9731
≥ 65154.89 ± 4.65
Gender
Male305.51 ± 3.890.1911
Female274.12 ± 4.03
Cell differentiation
Poor195.71 ± 4.140.021a
Moderate383.14 ± 3.07
Tumor size (cm)
< 5484.60 ± 3.790.2591
≥ 596.24 ± 4.91
Gross appearance
Borrmann I + II type103.72 ± 3.690.3251
Borrmann III + IV type475.10 ± 4.04
Site of tumor
Cardia93.60 ± 4.000.371
Body83.84 ± 5.57
Antrum405.34 ± 3.682
Lymphatic metastasis
Positive316.03 ± 4.160.041a
Negative263.87 ± 3.60
Depth of cancer invasion
T2114.71 ± 5.030.5861
T3445.02 ± 3.78
T422.02 ± 1.37
TNM Stage
I20.82 ± 0.720.3851
II124.02 ± 3.31
III355.34 ± 4.12
IV85.00 ± 4.49
Distal metastasis
Positive63.67 ± 3.220.4441
Negative515.00 ± 4.07